[重复] 同标题已决策 · wire:https://www.globenewswire.com/news-release/2026/10/27/3388771/0/en/nautilus-biotechnology-reports-third-quarter-2026-financial-results.html

Third Quarter 2026 Financial Results
Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant revenue from the Company’s activities related to the grant awarded from The Michael J. Fox Foundation during the period, and service revenue for the sales of services under the Iterative Mapping Early Access Program.
Operating expenses were $16.9 million for the third quarter of 2026, a $1.5 million or 10% increase compared to $15.5 million for the corresponding prior year period. The increase in operating expenses is attributable to higher laboratory and professional services and higher salaries and related benefits expense, partially offset by lower facilities expenses.
Net loss was $15.6 million for the third quarter of 2026, as compared to the net loss of $13.6 million for the corresponding prior year period.
Cash, cash equivalents, and investments were $114.3 million as of September 30, 2026.
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the third quarter 2026 financial results, business developments and outlook before market open on Tuesday, October 27, 2026, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at:
www.nautilus.bio
.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding operating expenses and cash runway, including any impact thereon from our reallocation of resources; expectations with respect to any revenue timing or projections; expectations with respect to the development required for and the timing of the launch of the Nautilus Voyager
TM
platform, our proteoform applications roadmap and full commercial availability of our proteoform and/or broadscale products and/or services; the functionality and performance of the Nautilus Voyager platform, its potential impact on providing proteome or proteoform access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery; expectations regarding platform specifications required by potential customers and partners and the timeline for adoption of the Nautilus Voyager platform by researchers; and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: the Nautilus Voyager product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines, or that we will receive the full amount of the SEEDS funding, which may be reduced, delayed or terminated. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2026 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of September 30, 2026 and December 31, 2025 (Unaudited)
(in thousands)
September 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
10,467
$
12,388
Short-term investments
76,109
91,018
Prepaid expenses and other current assets
3,661
2,557
Total current assets
90,237
105,963
Property and equipment, net
5,268
3,457
Operating lease right-of-use assets
24,592
27,773
Long-term investments
27,767
52,739
Other long-term assets
1,060
1,180
Total assets
$
148,924
$
191,112
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
1,265
$
943
Accrued expenses and other liabilities
4,359
3,177
Current portion of operating lease liabilities
4,134
3,832
Total current liabilities
9,758
7,952
Operating lease liabilities, net of current portion
22,607
26,187
Total liabilities
32,365
34,139
Stockholders’ equity:
Preferred stock
—
—
Common stock
13
13
Additional paid-in capital
493,940
488,737
Accumulated other comprehensive income (loss)
(572
)
243
Accumulated deficit
(376,822
)
(332,020
)
Total stockholders’ equity
116,559
156,973
Total liabilities and stockholders’ equity
$
148,924
$
191,112
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands, except share and per share data)
2026
2025
2026
2025
Revenue:
Grant revenue
$
208
$
—
$
388
$
—
Service revenue
26
—
36
—
Total revenue
234
—
424
—
Cost of revenue:
Cost of service revenue
24
—
39
—
Total cost of revenue
24
—
39
—
Operating expenses:
Research and development
10,176
9,605
29,496
31,535
Selling, general and administrative
6,771
5,867
19,513
19,878
Total operating expenses
16,947
15,472
49,009
51,413
Other income (expense):
Interest income
1,173
1,903
3,922
6,214
Other expense
(72
)
(5
)
(100
)
(21
)
Total other income
$
1,101
$
1,898
$
3,822
$
6,193
Net loss
$
(15,636
)
$
(13,574
)
$
(44,802
)
$
(45,220
)
Net loss per share attributable to common stockholders, basic and diluted
$
(0.12
)
$
(0.11
)
$
(0.35
)
$
(0.36
)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
127,238,065
126,305,122
127,005,067
126,218,587
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2026 and 2025 (Unaudited)
Nine Months Ended September 30,
(in thousands)
2026
2025
Cash flows from operating activities
Net loss
$
(44,802
)
$
(45,220
)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense
3,812
5,373
Amortization of operating lease right-of-use assets
3,180
3,529
Depreciation
884
1,348
Amortization (accretion) of premiums (discounts) on securities, net
(36
)
(1,286
)
Changes in operating assets and liabilities:
Prepaid expenses and other assets
(982
)
149
Accounts payable
48
(71
)
Accrued expenses and other liabilities
1,066
1,332
Operating lease liabilities
(3,277
)
(3,475
)
Net cash used in operating activities
(40,107
)
(38,321
)
Cash flows from investing activities
Proceeds from maturities of securities
76,596
74,241
Purchases of securities
(37,494
)
(38,771
)
Purchases of property and equipment
(2,409
)
(1,033
)
Net cash provided by investing activities
36,693
34,437
Cash flows from financing activities
Proceeds from exercise of stock options
1,233
26
Proceeds from issuance of common stock under employee stock purchase plan
142
87
Net cash provided by financing activities
1,375
113
Net decrease in cash, cash equivalents and restricted cash
(2,039
)
(3,771
)
Cash, cash equivalents and restricted cash at beginning of period
13,390
28,648
Cash, cash equivalents and restricted cash at end of period
$
11,351
$
24,877